Please assess the completion status of the following clinical trial:

Trial Title: Randomized Double Blind Control Trial on Effects of Ranolazine on New Onset Atrial Fibrillation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Male and female candidates (18 years of age and older) undergoing coronary bypass grafting surgery or valve repair or replacement - Aortic or Tricuspid or Pulmonary valves~* Patients who are not previously on Ranolazine~* Do not have a history of arrhythmia and are not on any antiarrhythmic therapy~* Patients with QTc on a 12 lead EKG of less than or equal to 460 ms~* Patients with estimated Glomerular Filtration Rate (GFR) greater than 30 mL/min/1.73 m2 on the initial lab work~* Available at least 48 hours before surgery~Exclusion criteria:~* Patients who are not undergoing above surgeries~* Patients undergoing surgery for mitral valve replacement/repair~* Patient with cirrhosis~* Pregnant patients~* Patients with chronic atrial fibrillation~* Patients who had prior adverse drug reactions or allergies to Ranolazine~* Patients who are already taking Ranolazine prior to the study~* Patient who are reported HIV Positive (as there are antiretroviral drug interactions)~* Patients who are on drugs listed in Appendix A prior to the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ranolazine (Type: ACTIVE_COMPARATOR): The antianginal properties of the drug are due to inhibition of the late inward sodium current, demonstrated in animal experiments and human studies that it can prevent atrial and ventricular arrhythmias.
- Placebo (Type: PLACEBO_COMPARATOR): Company generated placebo, will be similar in size and color to Ranolazine; and administered two times a day (12 hour intervals)

Based on this trial design, predict the completion outcome and termination type (if applicable).